Opportunity Information: Apply for PA 09 249
Apply for PA 09 249
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (SBIR R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Aug 12, 2009 and posted on Aug 12, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (SBIR R43/R44)" (Funding Opportunity Number PA-09-249) is a National Institutes of Health (NIH) Funding Opportunity Announcement aimed specifically at small business concerns that want to develop innovative approaches for controlling how stem cells and progenitor cells become specialized cell types. The core scientific focus is on identifying the factors, signals, and underlying mechanisms that drive differentiation of either embryonic stem cells or adult stem/progenitor cells, and it supports work carried out either in vitro (for example, in culture systems) or in vivo (within an organism or tissue environment). A key point is that the program is meant to stimulate new advances in stem cell differentiation and includes technology development that may not be strictly hypothesis-driven, making room for platform-building, enabling tools, and practical engineering advances that can unlock new capabilities in directing cell fate.
The long-term goal is clearly translational: to develop reliable methods to steer stem cells down specific lineage pathways so they can produce clinically useful replacement cells relevant to heart, lung, and blood diseases. This includes two broad therapeutic visions: producing differentiated replacement cells outside the body for delivery into patients, and inducing or guiding differentiation within the body so that stem or progenitor cells generate needed cell types directly in the tissue or organ context. In practical terms, the FOA is interested in the kinds of breakthroughs that make cell-based therapies more feasible, such as improved differentiation efficiency, better control over purity and identity of the resulting cells, stronger reproducibility, and approaches that are compatible with eventual clinical manufacturing and use.
From a funding mechanism standpoint, the opportunity uses the SBIR grant mechanisms R43/R44, which cover Phase I, Phase II, and Fast Track options. Phase I generally supports early feasibility and proof-of-concept work, Phase II supports more advanced R and D and development toward commercialization, and Fast Track is designed to accelerate a project from Phase I into Phase II with a combined application. The FOA is also described as running in parallel with companion announcements of the same scientific scope that target other mechanisms, including an STTR pathway (PA-09-250, R41/R42) and an exploratory/developmental research pathway (PA-09-248, R21). This parallel structure signals that NIH wanted to encourage the same overall science through multiple funding routes depending on the applicant type and collaboration model, while PA-09-249 is specifically the SBIR route for eligible small businesses.
In terms of topic alignment, the funding activity category is health, and the listed CFDA program areas include Cardiovascular Diseases Research (93.837), Lung Diseases Research (93.838), and Blood Diseases and Resources Research (93.839). Cost sharing or matching is not required, which is typical for many NIH grant programs and reduces barriers for small businesses. Eligibility is limited to small businesses, reinforcing the program emphasis on innovation with a commercialization pathway, product development mindset, and the potential to translate discoveries into tools, platforms, or therapeutic development pipelines.
Funding levels and award counts are not fixed. NIH notes that awards depend on the availability of funds and on receiving enough high-quality, meritorious applications. That means there is no guaranteed number of awards and no promised total program budget in the announcement text provided. An award ceiling of $250,000 is listed in the source data, which provides a sense of the maximum amount associated with the opportunity as summarized there, though actual awarded amounts in SBIR contexts can also depend on phase, scope, and NIH policy at the time of award. The opportunity was posted on August 12, 2009, with an original and final closing date of September 7, 2012, and an archive date of October 8, 2012, meaning it is no longer open for new submissions under that specific announcement.
Overall, PA-09-249 is best understood as an NIH SBIR solicitation aimed at pushing the science and technology of directed stem cell differentiation toward real-world cell-based therapies for major disease areas involving the heart, lungs, and blood. It invites small companies to tackle the hard problems that prevent stem cell biology from turning into dependable therapeutic products, including decoding differentiation mechanisms and building practical methods to generate the right cells at the right quality for eventual clinical use.
Frequently Asked Questions (FAQs)
What is the full title and funding opportunity number for this grant?
The opportunity is titled "Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (SBIR R43/R44)" and the Funding Opportunity Number is PA-09-249.
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA).
Who is this FOA intended for?
This FOA is aimed specifically at eligible small business concerns applying through the SBIR program.
What is the main scientific focus of PA-09-249?
The core focus is developing innovative approaches to control how stem cells and progenitor cells differentiate into specialized cell types. This includes identifying factors, signals, and mechanisms that drive differentiation of embryonic stem cells or adult stem/progenitor cells.
Does the FOA support work done in vitro, in vivo, or both?
Both. The FOA supports studies performed in vitro (for example, culture-based systems) and in vivo (within an organism or tissue environment).
Is this FOA limited to hypothesis-driven research?
No. The FOA explicitly supports technology development that may not be strictly hypothesis-driven, leaving room for platform-building, enabling tools, and practical engineering advances that improve the ability to direct cell fate.
What diseases or therapeutic areas does this opportunity target?
The announcement targets heart, lung, and blood diseases, with the overall goal of enabling cell-based therapies relevant to those areas.
What is the long-term translational goal of the FOA?
The long-term goal is to develop reliable methods to steer stem cells down specific lineage pathways to generate clinically useful replacement cells for heart, lung, and blood diseases.
What kinds of therapeutic approaches are within scope?
The FOA describes two broad therapeutic visions: (1) producing differentiated replacement cells outside the body for delivery into patients, and (2) inducing or guiding differentiation within the body so that stem/progenitor cells generate needed cell types directly in the tissue or organ environment.
What types of advances does NIH want to stimulate through this FOA?
The FOA emphasizes advances that make cell-based therapies more feasible, such as improved differentiation efficiency, better control of purity and identity of resulting cells, stronger reproducibility, and approaches compatible with eventual clinical manufacturing and use.
What funding mechanisms are used under PA-09-249?
The opportunity uses the SBIR grant mechanisms R43/R44, supporting Phase I, Phase II, and Fast Track options.
What is Phase I intended to support?
Phase I generally supports early feasibility and proof-of-concept work.
What is Phase II intended to support?
Phase II generally supports more advanced research and development and work moving toward commercialization.
What is the Fast Track option?
Fast Track is designed to accelerate a project from Phase I into Phase II by allowing a combined application that covers both phases.
Are there related or companion NIH announcements with the same scientific scope?
Yes. The FOA runs in parallel with companion announcements of the same scientific scope that target other mechanisms, including an STTR pathway (PA-09-250, R41/R42) and an exploratory/developmental research pathway (PA-09-248, R21).
How does PA-09-249 differ from the companion announcements listed?
PA-09-249 is specifically the SBIR route for eligible small businesses (R43/R44). The companion announcements use different mechanisms (STTR R41/R42 and R21) while covering similar scientific scope.
What is the funding activity category for this opportunity?
The funding activity category is health.
Which CFDA program areas are associated with this FOA?
The CFDA program areas listed are Cardiovascular Diseases Research (93.837), Lung Diseases Research (93.838), and Blood Diseases and Resources Research (93.839).
Is cost sharing or matching required?
No. Cost sharing or matching is not required.
Is there a guaranteed number of awards or a fixed total budget?
No. NIH indicates that awards depend on the availability of funds and the receipt of sufficient high-quality, meritorious applications. The number of awards and total program funding are not fixed in the information provided.
What is the award ceiling listed for this opportunity?
An award ceiling of $250,000 is listed in the source data summarizing the opportunity.
When was this FOA posted, and what were the closing dates?
The opportunity was posted on August 12, 2009. The original and final closing date is listed as September 7, 2012. The archive date is October 8, 2012.
Is PA-09-249 currently open for submissions?
No. Based on the final closing date and archive date provided, this specific announcement is no longer open for new submissions.
What is the overall purpose of NIH issuing this SBIR solicitation?
NIH issued PA-09-249 to push forward the science and technology of directed stem cell differentiation toward practical, real-world cell-based therapies for heart, lung, and blood diseases, particularly by enabling small businesses to develop methods, tools, and platforms that improve control, quality, and reproducibility of differentiated cell products.
Browse more opportunities from the same category: Health
Next opportunity: Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (STTR R41/R42)
Previous opportunity: Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 249
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 249) also looked into and applied for these:
| Funding Opportunity |
|---|
| Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (STTR R41/R42) Apply for PA 09 250 Funding Number: PA 09 250 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Transforming Primary Care Practice (R18) Apply for RFA HS 10 002 Funding Number: RFA HS 10 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $300,000 |
| NEI Research Grant for Secondary Data Analysis (R21) Apply for PAR 09 252 Funding Number: PAR 09 252 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research to Understand and Inform Interventions that Promote the Research Careers of Students in Biomedical and Behavioral Sciences (R01) Apply for RFA GM 10 008 Funding Number: RFA GM 10 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Non Human Primate Heart/Lung Transplantation Tolerance (U01, U19) Apply for RFA AI 09 041 Funding Number: RFA AI 09 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS) for Year 2009 (P50) Apply for PAR 09 254 Funding Number: PAR 09 254 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Erythropoiesis Components and Mechanisms (R01) Apply for PA 09 255 Funding Number: PA 09 255 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) Apply for PAR 09 256 Funding Number: PAR 09 256 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening Rehabilitation in District Environs (STRIDE) Apply for RFA 367 09 000001 Funding Number: RFA 367 09 000001 Agency: Nepal USAID Kathmandu Category: Health Funding Amount: $1,200,000 |
| 2010 NIH Directors Pioneer Award Program (DP1) Apply for RFA RM 09 010 Funding Number: RFA RM 09 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Network Infrastructure Support for Emerging Behavioral and Social Research Areas in Aging (R24) Apply for PAR 09 233 Funding Number: PAR 09 233 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Healthy Aging through Behavioral Economic Analyses of Situations (R01) Apply for RFA AG 10 008 Funding Number: RFA AG 10 008 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| Traumatic Brain Injury Protection and Advocacy Apply for HRSA 10 145 Funding Number: HRSA 10 145 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Effects of Gene Social Environment Interplay on Health and Behavior in Later Life (R01) Apply for RFA AG 10 006 Funding Number: RFA AG 10 006 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| AHRQ Grant Program for Large or Recurring Conferences (R13) Apply for PAR 09 257 Funding Number: PAR 09 257 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Centers for Medical Countermeasures Against Radiation (U19) Apply for RFA AI 09 036 Funding Number: RFA AI 09 036 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| NIGMS National Centers for Systems Biology (P50) Apply for PAR 09 258 Funding Number: PAR 09 258 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 11 001 Funding Number: RFA GM 11 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| AHRQ Small Grant Program for Conference Support (R13) Apply for PA 09 231 Funding Number: PA 09 231 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| USAID/Nigerias Proposed Malaria Project Invitation for Comments on Draft PD Apply for 620 09 020 Funding Number: 620 09 020 Agency: Nigeria USAID Abuja Category: Health Funding Amount: $110,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 249", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.